Pipeline
These investigational drugs come from Prof. Sachdev Sidhu’s lab at the University of Waterloo, and were done in collaboration with the UTSW of Dallas lab of Prof. Orson Moe.
We are dedicated to delivering innovative, safer, and more convenient therapies for patients with chronic kidney disease.
Our pipeline includes a highly selective, long-lasting EPOR receptor agonist, offering a more convenient and potentially safer treatment for anaemia.
Additionally, our groundbreaking approach to targeting FGF-23 provides a safer option for treating hypophosphatemic disorders such as XLH, ADHR, ARHR1-3, and TIO. This selective inhibition of FGF-23 may further benefit patients with chronic kidney disease.
